Last mentioned: Mar 19, 2026
Biofrontera and DarioHealth reported Q4 2025 results on March 19, 2026, highlighting a strategic shift from aggressive growth to sustainable profitability. While Biofrontera focuses on expanding its dermatology market share with Ameluz, DarioHealth is leveraging its B2B2C model to drive high-margin digital health revenue.
Biofrontera and DarioHealth reported Q4 2025 results that underscore a strategic shift toward high-margin clinical and enterprise markets. Both companies are prioritizing a path to profitability through disciplined cost management and the expansion of recurring revenue streams in dermatology and digital chronic care.
Armanino Foods and Biofrontera Inc. both reported record-breaking fourth-quarter and full-year 2025 financial results on March 19, 2026. These reports highlight strong execution in the specialty food and dermatological pharmaceutical sectors, respectively.
Biofrontera Inc. (BFRI) has achieved record financial results for the fourth quarter and full year 2025, signaling a significant shift in the dermatology market toward photodynamic therapy. The company's performance reflects robust adoption of its flagship product, Ameluz, and its proprietary RhodoLED lamp technology in the United States.
Biofrontera Inc. (Nasdaq: BFRI) has reported record-breaking financial results for the fourth quarter and full year 2025, signaling a major milestone in the commercial adoption of its photodynamic therapy (PDT) solutions. The company is leveraging increased market penetration of its flagship product, Ameluz, and its proprietary BF-RhodoLED lamps across U.S. dermatology practices.